Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme

被引:24
|
作者
Onishi, Manabu [1 ]
Kurozumi, Kazuhiko [1 ]
Ichikawa, Tomotsugu [1 ]
Date, Isao [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama 7008558, Japan
关键词
cilengitide; bevacizumab; angiogenesis; invasion; GELATINASE-B MMP-9; BRAIN-TUMORS; INTEGRIN ALPHA(V)BETA(3); RECURRENT GLIOBLASTOMA; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; SINGLE-AGENT; PHASE-II; IN-VIVO; CILENGITIDE;
D O I
10.2176/nmc.ra2013-0200
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Despite advances in surgical and medical therapy, glioblastoma multiforme (GBM) remains a fatal disease. There has been no significant increase in survival for patients with this disease over the last 20 years. Tumor vasculature formation and glioma cell invasion along the white matter tracts both play a pivotal role in glioma development. Angiogenesis and invasion are the major factors believed to be responsible for treatment resistance in tumors, and a better understanding of the glioma invasion and angiogenesis mechanisms will lead to the development of potential new treatments. In this review, we focus on the molecular characteristics of angiogenesis and invasion in human malignant glioma. We discuss bevacizumab and cilengitide, which are used to inhibit angiogenesis in GBM.
引用
收藏
页码:755 / 763
页数:9
相关论文
共 50 条
  • [21] Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
    Pircher, Andreas
    Hilbe, Wolfgang
    Heidegger, Isabel
    Drevs, Joachim
    Tichelli, Andre
    Medinger, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2011, 12 (10): : 7077 - 7099
  • [22] New Anti-Angiogenic Therapy for Glioblastoma With the Anti-Depressant Sertraline
    Tsuboi, Nobushige
    Otani, Yoshihiro
    Uneda, Atsuhito
    Ishida, Joji
    Suruga, Yasuki
    Matsumoto, Yuji
    Fujimura, Atsushi
    Fujii, Kentaro
    Matsui, Hideki
    Kurozumi, Kazuhiko
    Date, Isao
    Michiue, Hiroyuki
    CANCER MEDICINE, 2024, 13 (20):
  • [23] Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma
    Sasayama, Takashi
    Nagashima, Hiroaki
    Irino, Yasuhiro
    Tanaka, Kazuhiro
    CANCER SCIENCE, 2022, 113 : 1565 - 1565
  • [24] Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma
    Zhang, Ashley B. B.
    Mozaffari, Khashayar
    Aguirre, Brian
    Li, Victor
    Kubba, Rohan
    Desai, Nilay C.
    Wei, Darren
    Yang, Isaac
    Wadehra, Madhuri
    CANCERS, 2023, 15 (03)
  • [25] Identification of the hidden survival advantage for anti-angiogenic therapy in glioblastoma
    Nabors, Burt
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (01) : 72 - 74
  • [26] Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme
    Gossmann, A
    Helbich, TH
    Kuriyama, N
    Ostrowitzki, S
    Roberts, TPL
    Shames, DM
    van Bruggen, N
    Wendland, MF
    Israel, MA
    Brasch, RC
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2002, 15 (03) : 233 - 240
  • [27] ANTI-ANGIOGENIC THERAPY INCREASES TUMOR ASSOCIATED MACROPHAGES (TAMS) IN RECURRENT GLIOBLASTOMA (GBM) PATIENTS
    Lu-Emerson, Christine
    Snuderl, Matija
    Davidson, Christian
    Kirkpatrick, Nathaniel D.
    Huang, Yuhui
    Duda, Dan G.
    Ancukiewicz, Marek
    Stemmer-Rachamimov, Anat
    Batchelor, Tracy T.
    Jain, Rakesh K.
    NEURO-ONCOLOGY, 2012, 14 : 110 - 110
  • [28] Anti-angiogenic therapies in the management of glioblastoma
    Schulte, Jessica D.
    Aghi, Manish K.
    Taylor, Jennie W.
    CHINESE CLINICAL ONCOLOGY, 2021, 10 (04)
  • [29] ANTI-ANGIOGENIC ISOFORMS OF VEGF - A KEY TO ANTI-ANGIOGENIC THERAPY
    Bates, D. O.
    Harper, S. J.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3207 - 3208
  • [30] Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors
    Dey, Nandini
    De, Pradip
    Brian, Leyland-Jones
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (10): : 1675 - 1698